EGFR and breast carcinoma: At the molecular level, HER2 overexpression in ER+ breast cancer cells suffices to drive tamoxifen resistance, and elevated levels of EGFR and HER2 are detected in tamoxifen-resistant clones following long-term exposure of ER+ breast cancer cells to tamoxifen.